Secondary endpoints defined as tumor tissue infiltration with CD4+, CD8+ T-cells and CD20+ B-cells, lymphocytic response measured through cytokine concentrations (e.g., NFα, IFN-γ, RANTES) and antibody response (e.g., IL-10, IL-6) in patients’ blood, prostate and skin biopsies were positive. The gene discussed is CCL5; the disease is neoplasm.